Ocugen Inc (OCGN) - News Archive

In a significant development for the treatment of genetic eye diseases, Ocugen, Inc. announced that the first patient has been dosed in its Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST, a novel mo...

Charting Uncharted Waters: Ocugen s Ground-breaking Endeavours in Stargardt Disease Treatment In a realm where hope often flickers amidst shadow, Ocugen Inc. a luminary in the field of biotechnology, emerges as a beacon...

Data and Safety Monitoring Board Endorses Continued Investigation of OCU410 in Phase 2 ArMaDa Clinical Trial MALVERN, Pa. Dec. 19, 2024 Ocugen, Inc. (NASDAQ: OCGN), a pioneering biotechnology firm known for its focus on...

In an era where breakthroughs in biotechnology can redefine treatment landscapes for debilitating conditions, Ocugen, Inc. (NASDAQ: OCGN) is making significant strides with its gene therapy candidates targeting rare ret...

The recent announcement from Ocugen, Inc. regarding their preliminary findings from the OCU410 ArMaDa clinical trial sheds light on a potential breakthrough in treating geographic atrophy (GA), secondary to dry age-rela...

In a notable turn of events, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology firm distinguished by its commitment to the discovery, development, and commercialization of pioneering gene and cell therapies, biologics, and v...

In a significant development for the biotech sector, Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its investigational new drug application fo...

Ocugen Advances Gene Therapy for Stargardt Disease as Phase 1/2 GARDian Trial Dosing Concludes In a significant development for the biotechnology sector, Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosin...

Precision Medicine Advancements: Ocugen, Inc. s Expanded Access Program for Retinitis Pigmentosa Receives FDA Green LightMALVERN, Pa., Aug. 05, 2024 In a significant stride towards the treatment of retinitis pigmentosa...

MALVERN, Pa., Aug. 02, 2024 - Ocugen, Inc. (Nasdaq: OCGN), a renowned biotechnology company focused on revolutionizing gene and cell therapies and vaccines, has successfully closed its underwritten public offering of 30...

In a profound move aimed at propelling its groundbreaking gene and cell therapies and vaccines, biotechnology company Ocugen, Inc. has successfully priced its underwritten public offering of common stock at $1.15 per sh...

Ocugen, a biopharmaceutical company, recently announced that the Data and Safety Monitoring Board (DSMB) has approved the enrollment of patients in High Dose Cohort 3 of their GARDian Study for the treatment of Stargard...

Ocugen, Inc. Makes Critical Advances with Phase 3 liMeliGhT Clinical Trial for OCU400; First Patient Successfully DosedMALVERN, Pa., June 20, 2024 In a milestone achievement underscoring its innovative approach to treat...

Imminent Deadline Approaches for Ocugen Investors to Participate in Securities Class Action, Investigated by Faruqi & Faruqi, LLP New York, June 5, 2024 Faruqi & Faruqi, LLP, a preeminent national securities law firm, i...

Ocugen Achieves Key Milestones in Advancing Gene Therapy Programs for Geographic Atrophy and Retinitis Pigmentosa MALVERN, Pa., May 31, 2024 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a forefront contender i...

The esteemed Pomerantz Law Firm has recently announced the initiation of a class action lawsuit against Ocugen, Inc. (NASDAQ: OCGN). Shareholders who have invested in the company are strongly encouraged to contact Danie...

National law firm Bragar Eagel & Squire, P.C. has recently informed investors about the initiation of class action lawsuits on behalf of stockholders of HireRight Holdings Corporation (NYSE: HRT), Ocugen, Inc. (NASDAQ:...

Ocugen Announces Completion of Dosing in Second Cohort of Phase 1/2 Trial for Stargardt Disease Gene Therapy By MALVERN, Pa., May 15, 2024 Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company dedicated to pioneering adv...

In an exciting announcement, Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company known for its groundbreaking gene and cell therapies, has declared a dividend of newly designated Series C Preferred Stock. This...

Extensive strides have been made in medical and scientific research propelling gene therapy to the forefront. One such clinical advancement involves Ocugen Inc., a biotech authority focused on conceiving, developing and...